CRS 207

Drug Profile

CRS 207

Alternative Names: ANZ-207; Cancer vaccine - Aduro BioTech; CRS-207; Listeria monocytogenes-expressing mesothelin - Aduro Biotech

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Cerus Corporation; Chugai Pharmaceutical; Johns Hopkins University; Merck
  • Developer Aduro BioTech
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Mesothelioma
  • Preclinical Gastric cancer
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 09 Jan 2017 Preclinical trials in Gastric cancer in USA (Parenteral) before January 2017
  • 09 Jan 2017 Aduro BioTech and Merck agree to co-develop CRS 207 in combination with pembrolizumab for Gastric cancer
  • 09 Jan 2017 Aduro Biotech and Merck plan a phase I trial for Gastric cancer (Combination therapy, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top